Nigil Haroon, MD, PhD

Ankylosing spondylitis is a chronic inflammatory arthritis that affects young men and women resulting in significant disability and reduced quality of life. The pathogenesis is not well understood and there is no cure.

Vision: To expedite the development of novel therapeutics, relieve suffering and prevent deformities in patients living with ankylosing spondylitis (AS).

Dr. Haroon's research focuses on three broad themes:
1. Therapeutic targeting of MIF in AS.
2. The interplay of antigen processing and cellular trafficking in the pathogenesis of AS, with emphasis on the role of SEC16A and its interactome in AS pathogenesis.
3. Personalized medicine approach to treatment of AS

Related Links

For a list of Dr. Haroon's publications, please visit PubMed, Scopus or ORCID.

Clinician Scientist, University Health Network
Assistant Professor of Medicine and Rheumatology, University of Toronto
Chair, Wait Time Alliance Initiative, Canadian Rheumatology Association
Member, Research Ethics Board, University Health Network
Faculty, School of Graduate Studies, Institute of Medical Sciences, University of Toronto
Graduate Faculty Member, Toronto Musculoskeletal Center, University of Toronto